(Total Views: 713)
Posted On: 11/11/2020 2:14:11 PM
Post# of 154897
We have seen some very good developments today and that was, overall, a good Proactive Video.
However, Dr.NP has to finally learn that he must get his facts straight and stop exaggerating.
At 4:17 in the video, Dr.NP clearly says that CytoDyn receive a BTD for GvHD.
Feel free to use the link below which will take you to the exact clip.
Video Link: https://youtu.be/pR-5QPyp8o8?t=257
The fact is that on January 12, 2020, the FDA granted CytoDyn "Orphan Drug" designation for GvHD -- not BTD. There's a very big difference.
PR Link: https://www.cytodyn.com/investors/news-events...n-with-the
Lastly, this is not the first time Dr.NP has discussed dividend distributions.
If CytoDyn remains independent, it will become an extremely profitable company with minimal overhead and near zero R&D expense – because there is no need to develop, license, or buy another molecule.
If CytoDyn is not acquired it could easily become a cash machine. With top line revenue falling to the bottom line, net income will have no place to go other than debt repayment, share buyback, and dividends.
However, I will be very surprised if there is a multi-dollar dividend per share in calendar 2021. At a certain point, you have to decide if you are going to take everything that Dr.NP says at face value (and be repeatedly disappointed when his predictions do not materialize) -- or run the numbers yourself and temper your expectations.
However, Dr.NP has to finally learn that he must get his facts straight and stop exaggerating.
At 4:17 in the video, Dr.NP clearly says that CytoDyn receive a BTD for GvHD.
Feel free to use the link below which will take you to the exact clip.
Video Link: https://youtu.be/pR-5QPyp8o8?t=257
The fact is that on January 12, 2020, the FDA granted CytoDyn "Orphan Drug" designation for GvHD -- not BTD. There's a very big difference.
PR Link: https://www.cytodyn.com/investors/news-events...n-with-the
Lastly, this is not the first time Dr.NP has discussed dividend distributions.
If CytoDyn remains independent, it will become an extremely profitable company with minimal overhead and near zero R&D expense – because there is no need to develop, license, or buy another molecule.
If CytoDyn is not acquired it could easily become a cash machine. With top line revenue falling to the bottom line, net income will have no place to go other than debt repayment, share buyback, and dividends.
However, I will be very surprised if there is a multi-dollar dividend per share in calendar 2021. At a certain point, you have to decide if you are going to take everything that Dr.NP says at face value (and be repeatedly disappointed when his predictions do not materialize) -- or run the numbers yourself and temper your expectations.
(11)
(0)
